litlas
Log inCreate account

Michael R. McClung

Active 1977–2025

Also published as
MICHAEL R. McCLUNG
126
Papers
32,351
Citations
89
h-index
124
i10-index

Citations

Citations per year for Michael R. McClung1979: 2 citations1981: 3 citations1982: 4 citations1983: 2 citations1984: 4 citations1985: 2 citations1986: 3 citations1987: 1 citations1988: 3 citations1990: 3 citations1992: 6 citations1993: 6 citations1994: 4 citations1995: 18 citations1996: 29 citations1997: 40 citations1998: 34 citations1999: 59 citations2000: 83 citations2001: 76 citations2002: 125 citations2003: 129 citations2004: 127 citations2005: 137 citations2006: 216 citations2007: 173 citations2008: 245 citations2009: 183 citations2010: 249 citations2011: 246 citations2012: 246 citations2013: 194 citations2014: 202 citations2015: 233 citations2016: 223 citations2017: 246 citations2018: 233 citations2019: 658 citations2020: 937 citations2021: 801 citations2022: 703 citations2023: 498 citations2024: 913 citations2025: 476 citations2026: 11 citations1980: no citations, so this year is not shown1989: no citations, so this year is not shown1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,183 citing papers, 22.2% of this breakdownChina: 1,096 citing papers, 11.1% of this breakdownUnited Kingdom: 768 citing papers, 7.8% of this breakdownCanada: 460 citing papers, 4.7% of this breakdownItaly: 418 citing papers, 4.3% of this breakdownAustralia: 381 citing papers, 3.9% of this breakdownGermany: 380 citing papers, 3.9% of this breakdownSwitzerland: 324 citing papers, 3.3% of this breakdownFrance: 317 citing papers, 3.2% of this breakdownBelgium: 315 citing papers, 3.2% of this breakdownJapan: 289 citing papers, 2.9% of this breakdownNetherlands: 258 citing papers, 2.6% of this breakdown
0%22.2%Other 26.9%

Institutions

Fields

  • Medicine74.5%
  • Biochemistry, Genetics and Molecular Biology18.4%
  • Engineering1.8%
  • Neuroscience0.9%
  • Nursing0.8%
  • Immunology and Microbiology0.6%
  • Other3%

Topics

  • Bone health and osteoporosis research20%
  • Bone health and treatments11.9%
  • Bone Metabolism and Diseases10.7%
  • Bone and Joint Diseases4.5%
  • Hip and Femur Fractures3.5%
  • Parathyroid Disorders and Treatments2.8%
  • Other46.6%

Coauthors

All papers

Open in search
  1. Osteoporosis

    Authors: Juliet Compston, Michael R. McClung, William D. Leslie - The Lancet 2019 cited by 2,284

  2. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update

    Authors: Pauline M. Camacho, Steven M. Petak, Neil Binkley, Dima L. Diab, Leslie S. Eldeiry, Azeez Farooki, Steven T. Harris, Daniel L. Hurley, Jenny Kelly, E. Michael Lewiecki, Rachel Pessah‐Pollack, Michael R. McClung, Sunil J. Wimalawansa, Nelson B. Watts - Endocrine Practice 2020 cited by 1,109

  3. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

    Authors: Steven R. Cummings, Javier San Martín, Michael R. McClung, Ethel S. Siris, Richard Eastell, Ian R. Reid, Pierre Delmas, Holly Brenza Zoog, Matt Austin, Andrea Wang, Štěpán Kutílek, Silvano Adami, José Zanchetta, Cesar Libanati, Suresh Siddhanti, Claus Christiansen - New England Journal of Medicine 2009 cited by 3,442

  4. Romosozumab in Postmenopausal Women with Low Bone Mineral Density

    Authors: Michael R. McClung, Andreas Grauer, Steven Boonen, Michael A. Bolognese, Jacques P. Brown, Adolfo Díez‐Pérez, Bente Langdahl, Jean‐Yves Reginster, José Zanchetta, Scott M. Wasserman, Leonid Katz, Judy Maddox, Yuching Yang, Cesar Libanati, Henry G. Bone - New England Journal of Medicine 2014 cited by 1,235

  5. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

    Authors: Steven R. Cummings, Serge Ferrari, Richard Eastell, Nigel Gilchrist, Jens‐Erik Beck Jensen, Michael R. McClung, Christian Roux, Ove Törring, Ivo Valter, Andrea T Wang, Jacques P. Brown - Journal of Bone and Mineral Research 2017 cited by 709

  6. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

    Authors: for the IOF-IFCC Bone Marker Standards Working Group, Samuel D Vasikaran, Richard Eastell, Olivier Bruyère, A. Joseph Foldes, Patrick Garnero, Andrea Griesmacher, Michael R. McClung, Howard A. Morris, Stuart L. Silverman, Tommaso Trenti, D. A. Wahl, Cyrus Cooper, J. A. Kanis - Osteoporosis International 2010 cited by 1,172

  7. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

    Authors: Michael R. McClung, Jacques P. Brown, Adolfo Díez‐Pérez, Heinrich Resch, John Caminis, Paul Meisner, Michael A. Bolognese, Stefan Goemaere, Henry G. Bone, José Zanchetta, Judy Maddox, Sarah Bray, Andreas Grauer - Journal of Bone and Mineral Research 2018 cited by 231

  8. Denosumab in Postmenopausal Women with Low Bone Mineral Density

    Authors: Michael R. McClung, E. Michael Lewiecki, Stanley Cohen, Michael A. Bolognese, Grattan C. Woodson, Alfred H. Moffett, Munro Peacock, Paul D. Miller, Samuel Lederman, Charles H. Chesnut, Douglas Lain, Alan Kivitz, Donna Holloway, Charlie Zhang, Mark Peterson, Pirow Bekker - New England Journal of Medicine 2006 cited by 1,215

  9. Skeletal responses to romosozumab after 12 months of denosumab

    Authors: Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente Langdahl, Yifei Shi, Jen Timoshanko, Cesar Libanati, Arkadi Chines, Mary Oates - JBMR Plus 2021 cited by 73

  10. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis— 2020 Update Executive Summary

    Authors: Pauline M. Camacho, Steven M. Petak, Neil Binkley, Dima L. Diab, Leslie S. Eldeiry, Azeez Farooki, Steven T. Harris, Daniel L. Hurley, Jenny Kelly, E. Michael Lewiecki, Rachel Pessah‐Pollack, Michael R. McClung, Sunil J. Wimalawansa, Nelson B. Watts - Endocrine Practice 2020 cited by 202

  11. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

    Authors: Richard Eastell, Claus Christiansen, Andreas Grauer, Štěpán Kutílek, Cesar Libanati, Michael R. McClung, Ian R. Reid, Heinrich Resch, Ethel S. Siris, Daniel Uebelhart, Andrea Wang, G. Weryha, Steve Cummings - Journal of Bone and Mineral Research 2010 cited by 247

  12. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    Authors: Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos, Henry G. Bone, Bente Langdahl, Kenneth G. Saag, Ian R. Reid, Douglas P. Kiel, Ilaria Cavallari, Marc P. Bonaca, Stephen D. Wiviott, Tobias De Villiers, Ling Xu, Kurt Lippuner, Toshitaka Nakamura, Jean‐Yves Reginster, Jose Adolfo Rodriguez-Portales, C. Roux, José Zanchetta, Cristiano A. F. Zerbini, Jeong‐Gun Park, KyungAh Im, Abby Cange, Laura T. Grip, Norman Heyden, Carolyn DaSilva, Dosinda Cohn, Rachid Massaad, Boyd B. Scott, Nadia Verbruggen, Deborah M. Gurner, Deborah L. Miller, Micki L Blair, Adam B. Polis, S. Aubrey Stoch, Arthur C. Santora, Antonio Lombardi, Albert Leung, Keith D. Kaufman, Marc S. Sabatine, C. Mautalén, Z. Man, José Zanchetta, C. Magaril, Philip N. Sambrook, Jean‐Yves Reginster, Piet Geusens, Stefan Goemaere, Ben Hur Albergaria, Cristiano A. F. Zerbini, Marise Lazaretti Castro, Luiz Henrique de Gregório, Румен Стоилов, Anna-Maria I Borissova, Kiril Hristov Hristozov, Nataliya Temelkova, Ivona Daskalova, Stefka I Kuzmanova, Daniela Yaneva-Bichovska, Anastas Batalov, Pablo Riedemann, José Adolfo Rodríguez Portales, Hai Tang, Han-min Zhu, Zhenlin Zhang, Aijun Chao, Yali Hu, Zhiming Liu, Ju-ming Lu, Ming-cai Qiu, Xin Gao, Shaofen Zhang, Ling Xu, Weibo Xia, Eryuan Liao, Wenying Yang, Wen Wu, Kerong Dai, Renming Hu, Hai Tang, Juan José Jaller, Francisco Cabal, José Fernando Molina, Carlos Curé, Hernan Yupanqui-Lozno, Philippe Chalem, John Londoño, Maurício Abello, Edgardo D Tobias, William Otero, Tatjana Nikolić, Blazenka Miskic, J Štěpán, Václav Vyskočil, Libor Novosád, Jan Slesinger, Pavel Novosad, Erika Vlckova, Ladislav Bortlík, Eva Dokoupilová and 313 more - The Lancet Diabetes & Endocrinology 2019 cited by 169

  13. Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis

    Authors: Andrea Singer, Michael R. McClung, Oth Tran, C. D. Morrow, Shulamit Goldstein, Risa Kagan, Michele McDermott, Alon Yehoshua - Archives of Osteoporosis 2023 cited by 58

  14. Effects of denosumab on fracture and bone mineral density by level of kidney function

    Authors: Sophie A. Jamal, Östen Ljunggren, Catherine Stehman‐Breen, Steven R. Cummings, Michael R. McClung, Stefan Goemaere, Peter R. Ebeling, Edward Franek, YuChing Yang, Ogo Egbuna, Steven Boonen, Paul D. Miller - Journal of Bone and Mineral Research 2011 cited by 352

  15. Effect of Risedronate on the Risk of Hip Fracture in Elderly Women

    Authors: Michael R. McClung, Piet Geusens, Paul D. Miller, H Zippel, W. Bensen, Christian Roux, Silvano Adami, Ignac Fogelman, Terrence Diamond, Richard Eastell, Pierre J. Meunier, Richard D. Wasnich, Maria Greenwald, Jean‐Marc Kaufman, Charles H. Chesnut, Jean‐Yves Reginster - New England Journal of Medicine 2001 cited by 1,926

  16. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years

    Authors: Nelson B. Watts, John T. Grbic, Neil Binkley, Socrates E. Papapoulos, Peter Butler, Xiang Yin, Antoniette Tierney, Rachel B. Wagman, Michael R. McClung - The Journal of Clinical Endocrinology & Metabolism 2019 cited by 99

  17. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

    Authors: Michael R. McClung, Steven T. Harris, Paul D. Miller, Douglas C. Bauer, K. Shawn Davison, Larry Dian, David A. Hanley, David L. Kendler, Chui Kin Yuen, E. Michael Lewiecki - The American Journal of Medicine 2012 cited by 453

  18. Observations following discontinuation of long-term denosumab therapy

    Authors: Michael R. McClung, R.B. Wagman, Paul D. Miller, A. Wang, E. Michael Lewiecki - Osteoporosis International 2017 cited by 220

  19. Hormones and Aging: An Endocrine Society Scientific Statement

    Authors: Anne Rentoumis Cappola, Richard J. Auchus, Ghada El‐Hajj Fuleihan, David J. Handelsman, Rita R. Kalyani, Michael R. McClung, Cynthia A. Stuenkel, Michael O. Thorner, Joseph G. Verbalis - The Journal of Clinical Endocrinology & Metabolism 2023 cited by 82

  20. Vertebral Fractures: Clinical Importance and Management

    Authors: David L. Kendler, Douglas C. Bauer, K. Shawn Davison, Larry Dian, David A. Hanley, S. T. Harris, Michael R. McClung, Paul D. Miller, John T. Schousboe, Chui Kin Yuen, E. Michael Lewiecki - The American Journal of Medicine 2015 cited by 315

  21. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use

    Authors: Anthony B. Hodsman, Douglas C. Bauer, David W. Dempster, Larry Dian, David A. Hanley, Steven T. Harris, David L. Kendler, Michael R. McClung, Paul D. Miller, Wojciech P. Olszynski, Eric Orwoll, Chui Kin Yuen - Endocrine Reviews 2005 cited by 721

  22. Bone Mineral Density After Transitioning From Denosumab to Alendronate

    Authors: David L. Kendler, Arkadi Chines, Patricia Clark, Peter R. Ebeling, Michael R. McClung, Yumie Rhee, Shuang Huang, Robert Stad - The Journal of Clinical Endocrinology & Metabolism 2019 cited by 113

  23. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

    Authors: Michael R. McClung, MA Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente Langdahl, Judy Maddox, Yifei Shi, Maria Rojeski, Paul Meisner, Andreas Grauer - Osteoporosis International 2020 cited by 49

  24. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

    Authors: Paul D. Miller, Michael A. Bolognese, E. Michael Lewiecki, Michael R. McClung, Beiying Ding, Matthew Austin, Yu Liu, Javier San Martín - Bone 2008 cited by 574